Bisphosphonates

Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and solid tumor or multiple myeloma bone metastases

Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix

Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix

They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway

They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway

They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignanc...

Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and solid tumor or multiple myeloma bone metastases